Yosemite Management

The firm's entire thesis is expressed in one sentence on its website: to make cancer non-lethal within our lifetime. Every portfolio allocation appears oriented around oncology, spanning novel therapeutic platforms, AI-enabled drug discovery, and early-stage biotech ventures. This makes Yosemite a concentrated, single-outcome investment manager rather than a diversified life-science fund.

Yosemite maintains offices in Menlo Park, San Francisco, Greenwich, and Riyadh. The US locations align with traditional biotech venture hubs. The Riyadh office is notable and likely connects the firm to sovereign or private wealth in the Gulf, a region actively expanding its healthcare innovation allocations.

Altss research indicates coverage spanning early-stage seed investments through late-stage expansion rounds. This suggests Yosemite can support oncology companies from initial preclinical work through clinical trials and regulatory milestones, though specific portfolio holdings and check sizes remain private.

Yosemite is structured as a private equity asset manager, not a single-family office. While its capital base is undisclosed, the firm operates through a traditional venture fund model rather than managing the wealth of a single family. It qualifies as a pure-play VC with a biotech mandate.

No. Yosemite does not publicly disclose assets under management. Altss has no verifiable AUM figure from regulatory filings, public statements, or database coverage, and the firm's website makes no reference to fund size. The AUM status is therefore Undisclosed.